Introduction: Although the risk factors for lung cancer are well documented, whether previous radiation therapy (RT) to treat breast cancer (BC) increases the incidence of second primary lung cancer remains unclear. We determined the overall incidence of second primary lung cancer after previous RT for all clinical stages of BC.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide. 1 The risk factors for lung cancer include tobacco smoking, age, family history, medical or occupational radiation exposure, and other chronic inflammatory diseases, such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). 2, 3 Chronic inflammation and a microenvironment rich in inflammatory markers are related to carcinogenesis and have been regarded as hallmarks of cancer. [4] [5] [6] A history of prior cancer, such as lymphoma, head and neck cancer, or smoking-related cancer, is considered to be a unique risk factor for second primary lung cancer (SPLC).
occur after radiation therapy (RT) for breast cancer (BC). 12, 13 The incidence of second non-BC may be associated with the follow-up period, previous RT, and age. [14] [15] [16] Two recent Danish population-based studies claimed that patients with RT-treated BC are at a slightly increased risk for SPLC that is linearly dependent on the radiation dose. 17, 18 However, these two studies focused only on early-stage BC.
Regardless of the initial clinical stage of BC, whether RT for BC increases the overall incidence of SPLC remains unclear. Therefore, the aim of this study was to determine the overall incidence of SPLC after previous RT for all clinical stages of BC with consideration for age, comorbidities, insurance premiums, and hospital care level.
Material and Methods

Database
The authors analyzed the Taiwan Longitudinal Health Insurance Database (LHID), which is randomly abstracted from the National Health Insurance Research Database. The health insurance system in Taiwan enrolls more than 99 percent of the population (i.e., more than 23,000,000 insurants per year). The LHID includes the characteristics of outpatients, patients seen in emergency departments, and inpatients. Among all insurants, the LHID randomly collected data on 986,713 insurants with 20,795,043 medical events from January 1, 2000, to December 31, 2010. The composition and characteristics of the individuals in the LHID were normally distributed.
Study Design, Patients, and Ethics
The authors utilized the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding system to identify diagnoses and related procedures. Invasive BC is defined as ICD-9-CM code 174 and lung cancer is defined as ICD-9-CM code 162. Other types of malignancy are defined as ICD-9-CM codes 140 to 161, 163 to 173, and 175 to 239. High-grade dysplasia (carcinoma in situ) of BC was excluded. We enrolled female patients in whom BC was diagnosed from 2000 to 2010 and excluded patients younger than 18 years. We also excluded insurants with any prior history of cancer diagnosed before BC or with a history of prior BC before January 1, 2000.
RT is defined as ICD-9-CM procedure code 92.2 with subgroups and the National Health Insurance order codes for cobalt 60 teletherapy, 36006B or 36009B, and those for linear accelerator teletherapy, 36011B or 36012B. Breast surgery was defined as ICD-9-CM code 85.2 (conserving surgery), 85.3 (mammectomy), or 85.4 (mastectomy), and relevant subgroups. The following characteristics were provided by the LHID: age, sex, income level, hospital level, dates of events, urbanization level, location, and other comorbidities. The urbanization level was defined according to several indicators and based on the population size. Level 1 was designated as a population of at least 1,250,000, with political, economic, cultural, and metropolitan centers. Level 2 was defined as a population size between 500,000 and 1,249,999, with minor political, economic, and cultural centers. Level 3 was defined as a population size between 150,000 and 499,999. Level 4 was defined as a population size less than 149,999. 19 The study protocol was approved by the institutional review board of Tri-Service General Hospital, Taiwan, Republic of China (approval no. TSGH-IRB No. 2-105-05-082).
Comorbidities
The following comorbidities were assessed: hypertension (HTN) (ICD-9-CM code 401-405), diabetes mellitus (DM) (ICD-9-CM code 250), COPD (ICD-9-CM code 490-496), chronic kidney disease (ICD-9-CM code 585), ischemic heart disease (ICD-9-CM code 410-414), congestive heart disease (ICD-9-CM code 428-429), and stroke (ICD-9-CM code 430-438). The Charlson comorbidity index after removal of the aforementioned comorbidities and malignancy (CCI_R) was used to demonstrate the extent of the comorbidities.
Statistical Analysis
Statistical analysis was performed with SPSS software, version 20 (IBM Corp., Armonk, NY). The chi-square test and Fisher's exact test were used to compare categorical variables, and Student's t test was used to compare continuous variables between the RT group and non-RT group. Kaplan-Meier curve analysis and the log-rank test were used to demonstrate the cumulative risk for subsequent lung cancer. The hazard ratios (HRs) of SPLC and the other parameters of interest were calculated by multivariate Cox regression analysis. A p value less than 0.05 was considered statistically significant.
Results
Of the 986,713 individuals in the LHID, 8043 female patients with BC were enrolled in this study. All of the study participants were at least 18 years old and had BC that was newly diagnosed between 2000 and 2010. Application of the exclusion criteria resulted in exclusion of 635 patients; thus, only 7408 patients were selected for subsequent analysis. Among these, 5695 patients underwent RT and 1713 did not. Most RT cycles (w 98.30%) were administered with a linear accelerator. At the end of the follow-up period, lung cancer had been diagnosed in a total of 132 patients, including 128 in the RT group (2.25%) and four in the non-RT group (0.23%), respectively. The research algorithm is presented in Figure 1 .
The patient characteristics included lung cancer events, age, and comorbidities (Table 1) . Other demographic characteristics such as dates of events, urbanization level, location, hospital level of care, and insurance premium are presented in the Supplementary Data. Most patients with BC (>80%) were aged 40 years or older in both the RT and non-RT groups, and they were distributed equally among the age groups from 40 to 49 years, from 50 to 59 years, and 60 years or older. Initially, there were no significant differences in the incidences of comorbidities and CCI_R level between the RT and non-RT groups, with the exception of HTN (10.62% versus 6.89% [p < 0.001]) and DM (6.29% versus 3.85% [p < 0.001]). There were significant differences in location, urbanization level, hospital level of care, and insurance premium between the RT and non-RT groups at the beginning of this cohort study. Most patients with BC had their disease diagnosed in northern Taiwan, which has an aggregation of urbanization level 1 and 2 cities, and they were predominantly treated in medical centers (Supplementary Data).
The follow-up periods from the first RT exposure date to detection of SPLC varied from 1 to 11 years. The final characteristics at the end of the study (December 31, 2010) are also presented in Table 1 . By the end of the follow-up period, lung cancer had developed in a total of 128 individuals in the RT group and in only four individuals in the non-RT group (p < 0.001). There were no significant differences in the incidence of comorbidities (i.e., COPD, chronic kidney disease, ischemic heart disease, congestive heart disease, and CCI_R) between the RT and non-RT groups through December 31, 2010, with the exception of HTN (12.13% versus 8.58% [p < 0.001]), DM (8.31% versus 6.19% [p ¼ 0.002]), and stroke (1.72% versus 1.05% [p ¼ 0.028]). These comorbidities were more prevalent in the RT group.
The incidence of SPLC by years of follow-up until diagnosis is shown in Figure 2A . The SPLC of most individuals was diagnosed within 5 years after radiation exposure, particularly in the first 12 months. The Kaplan-Meier curves for SPLC-specific disease-free survival (DFS) for the RT and non-RT groups are shown in Figure 2B . There was a significant difference in DFS between groups according to the log-rank test (p < 0.001). The different types of initial surgery with or without RT are shown in Table 2 . The Kaplan-Meier curves for SPLC-specific DFS stratified by the type of surgeries are shown in Figure 3 . For conserving and other type of surgery, there was no significant difference in DFS between the RT and non-RT groups (Figs. 3A and 3B). However, in the mastectomy plus RT group, the occurrence of SPLC was higher than with mastectomy alone (1.04% versus 0.00%, respectively) ( Table 2 ). There was a significant difference in DFS between the mastectomy plus RT group and the mastectomy-alone group (p ¼ 0.021, log-rank test) (Fig. 3C ). For those who did not undergo any of the aforementioned breast operations, the occurrence of SPLC was extraordinarily higher in the RT group than in the non-RT group (10.63% versus 0.56% [p < 0.001]) ( Table 2 ). There was also a significant difference in SPLC-specific DFS between groups according to the log-rank test (p < 0.001) (Fig. 3D) . Figure 2 . Incidence of newly diagnosed second primary lung cancer after radiation therapy (RT) according to number of years of follow-up before diagnosis and a Kaplan-Meier curve of overall second primary lung cancer-specific disease-free survival. (A) In most of the individuals, second primary lung cancer was diagnosed within the first 3 years after RT. (B) Among females with breast cancer who were older than 18 years, disease-free survival of second primary lung cancer was stratified by RT using the log-rank test (p < 0.001). After adjustment for the season, location, urbanization, level of hospital, and insurance premium level by multivariate Cox regression, the adjusted HRs of RT exposure, age group, and comorbidities are presented in Table 3 . The adjusted HR of lung cancer was significantly (10-fold) higher in the RT group than in the non-RT group (p < 0.001, 95% confidence interval: 3.713-27.351) in multivariate analysis. Among all comorbidities, the HR Kaplan-Meier for secondary primary lung cancer-specific disease-free survival among females with breast cancer aged 18 years or older stratified by radiation therapy and the different surgical options with the log-rank test. The second primary lung cancer-specific disease-free survival was shorter for those who underwent radiation therapy alone or mastectomy plus radiation therapy.
for subsequent lung cancer decreased slightly only for HTN (HR ¼ 0.254, 95% confidence interval: 0.101-0.637, p ¼ 0.004). Compared with the HR of age group for patients with BC who were at least 60 years old, none of the investigated parameters had a statistically significant effect on the incidence of subsequent lung cancer in the Cox regression analysis (all p > 0.05). The overall incidence of lung cancer was 1785.18 per 100,000 people in the RT group and 181.47 per 100,000 people in the non-RT group. The incidence of SPLC in the RT group was much higher than in the non-RT group adjusted for all comorbidities.
Discussion
Treatment choices for BC are multidisciplinary and include a combination of surgical resection, RT, chemotherapy, hormone therapy, and targeted therapy. This study investigated whether RT, a frequently used therapeutic option for multidisciplinary treatment of BC, subjected patients to a greater risk for SPLC in an East Asian country. Despite inclusion of all BC stages, the overall occurrence of SPLC was predominant in the RT group (2.25% versus 0.23%) and was associated with a significantly increased risk (adjusted HR was increased 10.078-fold) compared with in the non-RT group after adjustment for age, comorbidities, dates of events, location, urbanization level, and insurance premium level. Most lung cancers among patients were diagnosed within the first 5 years after RT for BC. After stratification by the initial surgical treatment, SPLC-specific DFS was significantly shorter among those who underwent RT alone (no operation) than among those in the non-RT group.
Although some studies over the past few decades have focused on the connection between RT and SPLC, whether radiation exposure induces SPLC in patients with BC remains unclear. [15] [16] [17] [18] 20, 21 An older study published in 1994 reported a relationship between RT and SPLC. That study enrolled 8976 patients with BC between 1936 and 1971 and claimed that the estimated overall incidence of SPLC was nine cases per 10,000 women per year after irradiation with an average lung dose of 10 Gy and survival of more than 10 years. 22 However, only 18% of patients with BC in this cohort study underwent RT as part of initial treatment, which is relatively low, as compared with the current use of RT. Because the effect of mastectomy has prognostic value equivalent to that of conserving surgery plus adjuvant RT while providing less intraoperative blood loss, a shorter duration of surgery, and a shorter hospitalization period, the use of RT continues to increase. 23 Another possible bias of this study is the lack of suitable and sensitive diagnostic tools at that time, including highresolution computed tomography, which gave rise to omission of ground glass opacity and thus may have resulted in underestimation of the occurrence of SPLC.
The other three recent studies investigated the incidence of SPLC among patients with early-stage BC 15, 17, 18 Note: The HR of secondary primary lung cancer was calculated by using multivariate Cox regression. After adjustment of the seasons, location, urbanization, level of hospital, and insured premium, the HRs of surgery, age and the comobidities were demonstrated. The incidence rates of lung cancer per 100,000 people were significantly higher in radiation group. a Per 100,000 people. and demonstrated an increased risk for subsequent lung cancer associated with the given radiation dose for BC. 17, 18 In these studies, 51% to 57% of patients with early-stage BC underwent RT and lung cancer subsequently developed in approximately 0.7% to 2.0% of all irradiated patients. Most SPLC cases were diagnosed 5 years after diagnosis of BC, and the median SPLC-specific DFS duration was 6 to 12 years. 15, 18 Compared with our study, after the data were stratified according to the initial type of surgery, the DFS for SPLC was even after irradiation among patients with BC who underwent a conserving operation or mammectomy. It is interesting to observe that there was no significant difference in SPLC-specific DFS between the RT and non-RT groups within the first 10 years (Figs. 3A and 3B) .
Those who underwent mammectomy or a conserving operation had relatively early stages of disease. In contrast, the patients with BC who underwent mastectomy plus RT were presumed to have clinically advanced stages, such as (1) stage IIIB/IIIC disease, (2) T3 tumors with four or more positive regional lymph nodes, or (3) positive axillary lymph nodes after mastectomy. As a result, we hypothesized that patients in whom SPLC developed had clinically advanced rather than earlystage BC.
As reported in the Supplementary Data, there were some significant differences in the initial and final characteristics between the RT and non-RT groups. Also, the date of events, location, urbanization level, and hospital levels of care were unevenly distributed. Among these parameters, multivariate Cox regression demonstrated colinearity of the location and urbanization level. One possible explanation for this result is the urbanrural gap and imbalance in the distribution of the medical facilities. There are at least 11 medical centers in northern Taiwan, but only one in eastern Taiwan. As a result, most patients with BC had their disease diagnosed and treated in northern Taiwan, which led to an uneven distribution of patients.
A Swedish study showed that women with BC who had a history of smoking and RT were at a higher risk for SPLC, but other socioeconomic effects or comorbidities that were associated with chronic inflammation response were not investigated. 24 The relationship between COPD and lung cancer was linked by interleukin-1, interleukin-6, tumor necrosis factor-a, and reactive oxygen species mediated by infiltration of macrophages, neutrophils, and T cells. [25] [26] [27] [28] Other comorbidities, such as HTN, DM, COPD, and subsequent cardiovascular sequelae, were also associated with a chronic inflammatory response and had similar effects on oncogenesis. 29, 30 Hence, such chronic inflammation may actually have an effect on the incidence of subsequent lung cancer, which should be further investigated in future studies.
The results of previous studies were mostly comparisons of the standardized incidence ratios of SPLC, whereas two studies reported the HRs of SPLC for patients with BC who underwent RT. 16, 17 In a Dutch population, after a median follow-up period of 5.4 years, 31,986 of 58,068 patients with invasive BC (55.08%) underwent RT. SPLC was diagnosed in a total of 301 patients (0.94%) between 1989 and 2003. Among women younger than 50 years, Schaapveld et al. found that RT significantly increased the risk for SPLC (2.31-fold). 16 Another Danish study that investigated the incidence of all second primary cancers in 46,176 patients in whom early-stage BC had been diagnosed between 1982 and 2007 reported that 23,627 patients (51.17%) underwent RT and the median follow-up period for the irradiated patients with BC was similarly 5 years. 17 The HR of SPLC for the RT group was 1.27-fold greater than for the non-RT group. The trend of HRs for latent lung cancer also increased over the follow-up period. However, this study focused only on early-stage BC. Those aged 70 years or older (9630 patients) and those not treated with an operation (3485 patients) were also excluded from this cohort, which may have caused selection bias, particularly for older women. Meanwhile, apart from age, smoking, and RT dose, race was also an important factor influencing the incidence of BC and subsequent SPLC. The cohorts of all of these studies were limited to white populations; therefore, there are limited data for Asian populations.
On the other hand, a study conducted in the United States reported that the average age-adjusted incidence of lung cancer was approximately 52.3 per 100,000 women, with 17.4 per 100,000 women younger than 65 years and 293.8 per 100,000 females 65 years or older of all races. Nevertheless, the overall incidences of SPLC in the present study for the non-RT and RT groups were 181.47 and 1785.18 per 100,000 women, respectively (Table 3 ). The incidence of lung cancer in each age subgroup of the RT group ranged from 1559.76 to 2250.80 per 100,000 women, as compared with 0.00 to 379.45 per 100,000 women in the non-RT group. After adjustment for comorbidities and other parameters, the incidence of lung cancer after BC in any age subgroup was also significantly higher in the RT group than in the non-RT group.
It is important to identify the strengths, biases, and limitations of this study when interpreting the results. This study was based on a nationwide survey of a large, randomized sampling of an Asian population. Because our study enrolled patients with all clinical stages of BC, our findings presumed that the risk for SPLC was higher in the BC population after radiation exposure, particularly for women with advanced-stage BC. Multivariate Cox regression showed that the influence of specific comorbidities on the occurrence of subsequent SPLC was negligible. Meanwhile, our study also provides further evidence that DFS of SPLC is significantly shorter among women who underwent mastectomy plus RT or RT alone, despite the use of other multidisciplinary treatments such as endocrine therapy, hormonal therapy, and chemotherapy.
There were some limitations to this study. First, the criteria for clinical and pathological staging of BC were unclear in the LHID. Although the type of treatment was utilized to roughly estimate the possible stages of BC, possible bias still existed. Second, whether the location of the subsequent lung cancer was ipsilateral or contralateral to the radiation exposure site was also unknown. Third, the radiation type, dosage, and other important cofactors such as smoking could not be determined from the LHID. Another possible factor that increased the SPLC diagnosis rate of advanced BC is relatively aggressive computed tomography of the thorax, which is not routinely performed during follow-up of patients with early-stage breast cancer after surgical resection. Finally, the histopathological subtype and clinical stage of the SPLC were not available for advanced analysis. Future studies should focus on determining whether BC and associated multidisciplinary treatments have an effect on the incidence of subsequent lung cancer.
The results of this study showed that RT for BC, which is an important treatment option, was correlated with a significant increase in the incidence of SPLC, particularly among older women or those with advanced-stage BC. Regardless of the clinical or pathological stage, RT for BC also significantly increased the risk for subsequent lung cancer relative to the risk in the non-RT population. Patients who undergo RT for multidisciplinary treatment of BC should be carefully monitored to detect potential SPLC.
